Exclusive Summary

• **Next-Gen BsAb + Dual-Payload ADC Technology**: UB138 integrates bispecific antibody targeting with a proprietary 'One Linker, Two Payloads' (L2P) platform to transcend traditional ADC limitations.
• **Addressing Tumor Heterogeneity & Resistance**: Delivers two distinct cytotoxic mechanisms simultaneously to induce synergistic killing, specifically designed to tackle tumor heterogeneity and drug resistance.
• **Strategic Co-development Opportunity**: Currently in early discovery, UB138 is explicitly designated for 'Co-development,' offering partners early access to a cutting-edge platform with reduced CMC complexity.

Asset Materials

Contact Us for Full Materials